fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

Updated on July 8, 2020

Stock/Share Code - AUROPHARMA

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 201903 Annual Report Page No: 147)

Below is the details of AUROPHARMA Aurobindo Pharma Ltd

Market Cap₹43,691 Cr.
Current Price ₹809.35 as on 14 Jul 20
52 Week High / Low Price₹750.5 / ₹281.15
Face Value₹1
Stock P/E27.17
Book Value₹206.07
Dividend Yield0.40 %
ROCE14.92 %
ROE14.42 %
Sales Growth (3yrs)10.21 %
SectorPharmaceuticals
IndustryPharmaceuticals - Indian - Bulk Drugs & Formln
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros:
Cons: The company has delivered a poor growth of 11.51% over past five years. Company has high debtors of 155.79 days.

Aurobindo Pharma Ltd Price Chart

Aurobindo Pharma Ltd Price Chart

Aurobindo Pharma Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Sun Pharma.Inds. ₹164.15 28.53 ₹113,788.46 Cr. 0.63 ₹399.84 Cr. -2.03 14.25 8184.94 11.19
2. Dr Reddy's Labs ₹3,983.15 33.39 ₹67,652.81 Cr. 0.49 ₹781.1 Cr. 71.52 10.41 4448.90 12.42
3. Cipla ₹632.3 33.79 ₹52,256.4 Cr. 0.46 ₹245.95 Cr. -33.02 -0.63 4376.19 10.94
4. Aurobindo Pharma 27.17 ₹43,690.51 Cr. 0.40 ₹419.07 Cr. -9.59 3.00 3345.67 14.92
5. Biocon ₹437.6 62.53 ₹42,564 Cr. 0.14 ₹123.4 Cr. -42.26 3.41 1581.00 13.39
6. Torrent Pharma. ₹35.95 39.00 ₹39,979.07 Cr. 0.72 ₹314 Cr. 121.13 4.85 1946.00 12.66
7. Cadila Health. ₹353.8 25.02 ₹35,278.17 Cr. 1.02 ₹373.9 Cr. -26.54 1.68 3638.10 15.35
8. Alkem Lab ₹2,474.9 24.26 ₹27,056.36 Cr. 0.97 ₹381.98 Cr. 88.60 13.26 2181.84 16.58

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Aurobindo Pharma Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019
Sales -2,4202,1883,0742,6862,3552,5593,1703,2483,2813,0793,2223,346
YOY Sales Growth %-1.12%-9.93%27.54%6.54%-2.70%16.93%3.14%20.91%39.32%20.32%1.62%3.00%
Expenses -1,8401,7002,0352,0221,8772,1622,5632,6502,5462,5282,5902,694
Material Cost %46%45%40%47%47%51%51%52%48%50%50%50%
Employee Cost %10%12%9%11%13%12%10%11%11%12%12%12%
Operating Profit5804891,039664478397607598734550631651
OPM %24%22%34%25%20%16%19%18%22%18%20%19%
Other Income5112293463413728303438
Interest91012131724314135322521
Depreciation738390909294101109109115118119
Profit before tax549407966595375282479585618433522549
Tax %17%24%22%25%18%20%21%21%26%24%24%24%
Net Profit455307753444308225381464460330398419
EPS in Rs7.785.2512.857.585.263.846.507.917.855.646.807.15
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales -2,2762,7493,1954,1304,2775,4247,1088,0699,1589,60710,27012,25812,927
Sales Growth %21.93%20.80%16.23%29.24%3.57%26.81%31.06%13.51%13.50%4.91%6.90%19.36%
Expenses -1,9172,5002,4973,1733,7044,4665,1875,8166,7057,2157,6009,83810,360
Material Cost %60%59%55%53%59%56%49%47%47%48%44%50%
Manufacturing Cost %11%10%10%10%11%11%9%10%10%10%10%11%
Employee Cost %7%6%7%7%9%8%7%8%9%10%11%11%
Other Cost %7%16%6%6%8%8%7%7%8%7%8%8%
Operating Profit3592506989575739581,9222,2532,4532,3922,6702,4202,567
OPM %16%9%22%23%13%18%27%28%27%25%26%20%20%
Other Income1197517229-30027736518711881189130
Interest598163552682502891322294553231113
Depreciation758295125143171186245263286355413461
Profit before tax345161712805-1385631,5191,9402,1482,1792,3431,9652,123
Tax %16%20%26%26%69%12%23%22%24%22%23%22%
Net Profit291129526594-434961,1721,5161,6271,7071,8131,5301,608
EPS in Rs5.352.329.352.010.008.4019.8525.5327.8028.7330.9426.1127.44
Dividend Payout %6%19%5%10%-68%9%7%9%9%9%8%10%

Compounded Sales Growth

  • 10 Years:: 16.12%
  • 5 Years:: 11.51%
  • 3 Years:: 10.21%
  • TTM:: 14.07%

Compounded Profit Growth

  • 10 Years:: 28.53%
  • 5 Years:: 5.56%
  • 3 Years:: -1.87%
  • TTM:: 16.69%

Return on Equity

  • 10 Years:: 24.48%
  • 5 Years:: 2.60%
  • 3 Years:: 7.91%
  • 1 Year:: 10.89%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Sep 2019
Share Capital -27272829292929295959595959
Equity Capital272728292929292959595959
Reserves1,1941,2941,8862,5402,4642,9103,9835,3306,8078,3789,92411,29212,016
Borrowings1,7562,1151,9452,3182,7942,7822,9253,2854,1653,0543,7194,5203,728
Other Liabilities -5185997359547041,1031,6381,5821,5341,5332,0922,2702,676
Trade Payables3554155147335859011,2361,1461,2791,2181,6291,8411,760
Advance from Customers233512614945766
Other liability items162181185209113188393431250308457423916
Total Liabilities3,4944,0344,5945,8415,9916,8258,57610,22612,56613,02315,79418,14118,478
Fixed Assets -8278731,0451,3501,6272,0121,9382,1902,5683,2123,3934,1504,290
Gross Block1,1341,2621,5271,9552,3632,9073,0093,5082,8313,7584,2925,446
Accumulated Depreciation3073894826057378961,0711,3182635478991,296
CWIP1252864995375581662042277429071,144789740
Investments2882693714936297088731,0131,1831,6821,9682,3392,476
Other Assets -2,2552,6062,6783,4613,1773,9385,5616,7968,0727,2229,28910,86310,972
Inventories6517369451,2611,2191,4321,7122,1452,4322,4343,4093,9714,296
Trade receivables7991,1061,1511,4801,4261,7312,9703,7094,3813,7744,4685,2324,810
Cash Equivalents2398751221411510113313424676232
Loans n Advances5856975944195044974085128999961,2401,569360
Other asset items-20-19-161791316546141929-14-74151,275
Total Assets3,4944,0344,5945,8415,9916,8258,57610,22612,56613,02315,79418,14118,478

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity -10553462455046253285902,457922527
Profit from operations3523827379785179561,9352,3162,4822,6722,420
Receivables-173-281-76-33379-310-1,287-667532-513-878
Inventory-104-84-207-31642-212-280-433-2-976-562
Payables9572108191-151315346-10538393229
Loans Advances-22-45-68-8685-8-44-92-12-2
Direct taxes-43-39-148-177-28-116-339-426-482-530-482
Other operating items000-12-391-3-4-110-126-198
Cash from Investing Activity --12-302-408-569-534-295-401-624-1,542-991-1,297
Fixed assets purchased-133-289-342-516-401-166-149-544-1,020-976-890
Fixed assets sold211831210222563
Investments purchased-85-69-73-200-15300-198-541-257-358
Investments sold17148039023002900
Interest received281724653417422
Dividends received000000000079
Invest in subsidiaries00000-137-2490000
Loans to subsidiaries0-10-3800-8-21-3000
Inter corporate deposits0000000-1000
Other investing items50310015-133102-16-15-133
Cash from Financing Activity --185161-14443-78-229-3135-1,329440599
Proceeds from shares20510137700
Proceeds from debentures00000000000
Redemption of debentures0-140-6-10-941000000
Proceeds from borrowings04441806221,1132871013780991952
Repayment of borrowings-113-48-108-90-149-352-7-110-1,157-238-65
Interest paid fin-59-55-56-33-68-98-70-59-42-49-127
Dividends paid-16-39-29-47-34-67-60-153-114-219-146
Application money refund00000000000
Other financing items0000000-28-23-45-14
Net Cash Flow-92-136-75118-108101-1051-414371-171

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %14%7%21%20%9%15%29%27%24%20%19%15%
Debtor Days128147132131122116153168175143159156
Inventory Turnover3.803.963.803.743.454.094.524.184.003.953.523.32

Announcements & News

Recent Announcements

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Aurobindo Pharma Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.